Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing the Utility of Peak Inspiratory Flow as a Predictor for COPD Exacerbations

NCT04360226 is registered in ClinicalTrials.gov with Respiratory Effectiveness Group as lead sponsor.

NCT NCT04360226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04360226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing the Utility of Peak Inspiratory Flow as a Predictor for COPD Exacerbations
Lead sponsor
Respiratory Effectiveness Group
Phase
Observational
Overall status
Completed
Start date
December 14, 2020
Completion date
January 25, 2024
Enrollment
400 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease